Skip to main content

Global Care Capital Inc. Closes Acquisition of ViraxClear and Portfolio Company, ViraxClear, Receives FDA Emergency Use Authorization and CE Marking

Written by Customer Service on . Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, April 20, 2020 (GLOBE NEWSWIRE) — Global Care Capital Corp. (CSE: HLTH, OTC: RSCZF, FRANKFURT: L6V1) (the “Company” or “Global Care”) is pleased to announce that ViraxClear, has obtained Emergency Use Authorization (EUA) by the Food and Drug Administration (“FDA”) for the COVID-19 test kits it distributes and markets. ViraxClear’s tests can be used by clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA). ViraxClear’s COVID-19 test kit also has CE marking allowing sales to the European Community, and to other global markets that accept a CE marking as valid regulatory approval following routine local product registration. 
The Company has conducted normal course due diligence to verify the FDA (EUA) and CE marking approvals for the antibody test kits that ViraxClear markets and distributes and its manufacturing partner, Shanghai Liangrun Biomedicine Technology Co. Ltd. manufactures. The Company will keep the market apprised of ongoing aggregate purchase orders for test kits received by ViraxClear, secured by customer deposit, in excess of US$100,000. Alex Somjen, president and chief executive officer of Global Care states: “We believe that this authorization is a significant step in helping this COVID-19 test to reach an even wider audience. We believe that serology tests are a potentially powerful tool for identifying anyone who has been infected, whether they have symptoms or not. Many experts agree that accessibility of widespread testing is an important element to ‘flattening the curve’. We look forward to ViraxClear pursuing their goal of increasing the availability of advanced and cost-effective COVID-19 testing solutions across the globe.”The company is not making any express or implied claims that it has the ability to treat the COVID-19 virus at this time.The Company also announces that its acquisition of ViralClear Rapid Test Corp (d/b/a ViraxClear), closed on April 17th, 2020, under the same terms set out in the Company’s news release dated April 16, 2020.The Company is fully disclosed of all material news at this time and has not published any paid for material.The Company wishes to note that the trade name VirexClear was used in the Company’s news release dated April 16th, 2020.  The Company confirms that the correct trade name is ViraxClear. The Company is also pleased to announce the appointment of Hybrid Financial on April 15th, 2020, as its Investor Relations Advisor, effective immediately.  The agreement with Hybrid Financial provides a monthly fee of CAD15,000 for an initial term of six months. About ViraxClearViraxClear focuses on commercializing novel products that address significant healthcare needs with a specific target on the novel coronavirus (COVID-19). The company’s main focus is marketing its ViraxClear Rapid IgM-IgG Combined Antibody Test. The ViraxClear Rapid IgM-IgG Combined Antibody Test for COVID-19 is a lateral flow immunoassay used to qualitatively detect both early and late marker IgG/IgM antibodies.About Global CareGlobal Care Capital is a global investment company which specializes in providing early stage financing to private and public companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining positions in early stage investment opportunities that adequately reflect the risk profile.GLOBAL CARE CAPITAL CORP.: Company Contact: Alex Somjen, President & CEOasomjen@globalcarecapital.comTel: 416-319-5744Neither the CSE nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release.This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933 (the “1933 Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration is available.Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.